Emyria Ltd

Emyria’s psilocybin program received ethics endorsement for treating resistant depression, and the Empax Centre was selected for a clinical trial partnership with Psyence Biomed. How does Emyria plan to leverage these developments to expand its clinical services portfolio or generate additional revenue?​

Emyria’s quarter-end cash balance was $646,000, with an estimated funding capacity for 0.5 quarters. Could management outline contingency funding strategies, including any expected capital raises, if revenue growth falls short?​